Abstract : The aim of this study was to assess the non-inferiority of on-demand OD inhaled corticosteroid ICS and fast-acting beta-2 agonist FABA combination therapy. Although regular inhalation of low-dose ICS and OD short-acting beta-2 agonist REG-ICS OD-SABA is said to be effective therapy for mild asthma, we investigated whether OD-ICS / FABA is as effective as REG-ICS OD-SABA. A network meta-analysis of randomized controlled trials was conducted to examine non-inferiority by comparing the ef cacy of NON-REG OD-ICS / FABA with REG-ICS OD-SABA for mild asthma. We also assessed the superiority of NON-REG OD-ICS / FABA to OD-SABA without any regular treatment NON-REG OD-SABA . PubMed, the Cochrane library database, and Scopus were searched to identify relevant articles with an outcome measure of the incidence of asthma control. A network meta-analysis was performed and the summary effect size was expressed as the mean difference MD with 95 con dence intervals CIs . The probability of being the best treatment for the outcome and the surface under the cumulative ranking curves were also calculated. Three randomized controlled trials of treatment for mild asthma met the criteria and were included in the study. Non-inferiority of NON-REG OD-ICS / FABA to REG-ICS OD-SABA MD, 0.17 ; 95 CI, 0.41 to 0.07 and superiority of NON-REG OD-ICS / FABA to NON-REG OD-SABA MD, 0.29 ; 95 CI, 0.49 to 0.08 were shown in patients with mild asthma. The respective probabilities of being the best treatment for asthma control were 91.2 , 8.8 and 0.2 for NON-REG OD-ICS / FABA, REG-ICS OD-SABA, and NON-REG OD-SABA, respectively, and the surface under the cumulative ranking curves were 1.0, 0.5, and 0.1, respectively. These results suggest that NON-REG OD-ICS / FABA is an effective alternative to REG-ICS OD-SABA for asthma control in patients with mild asthma.
Introduction
The frequency of patient hospitalization for acute exacerbation of bronchial asthma has decreased markedly in recent decades due to the global use of inhaled corticosteroids ICS 1 .
The 2014 revision of the Japanese Guidelines for Adult Asthma recommends treatment with regular ICS regardless of asthma severity because of the ef cacy of ICS for the suppression of airway in ammation and inhibition of asthma progression 2 . However, success in treating patients with asthma can be limited by poor adherence to daily inhaled medication 3 . On-demand OD use may reduce the in uence of poor adherence, and may lead to improved control of asthma and reduction in the requirement for regular use of ICS and beta-2 agonists. Randomized controlled trials RCTs have shown that OD use of an ICS with a fast-acting beta-2 agonist FABA without any regular treatments NON-REG OD-ICS / FABA might be an alternative to regular ICS plus OD-FABA REG-ICS OD-FABA in patients with mild asthma 4 . In these trials, FABA included not only short-acting beta-2 agonists but also formoterol, because formoterol is used for both maintenance and relief of symptoms because of its pharmacokinetic characteristics of fast action and long duration of action.
Another RCT did not demonstrate a significant difference in efficacy for asthma control between NON-REG OD-ICS / FABA and an OD-SABA without any regular treatment NON-REG OD-SABA 5 . An RCT in patients with moderate asthma showed the inferiority of NON-REG OD-ICS / FABA for asthma control relative to regular ICS with a long-acting beta-2 agonist LABA plus OD-SABA REG-ICS / LABA OD-SABA 6 .
We previously investigated the non-inferiority of NON-REG OD-ICS / FABA relative to REG-ICS OD-SABA or REG-ICS / LABA OD-SABA in patients with mild to moderate asthma in a network meta-analysis of RCTs. Non-inferiority of NON-REG OD-ICS / FABA to REG-ICS OD-SABA or REG-ICS / LABA OD-SABA was not observed, but the probability of being the best treatment was higher for NON-REG OD-ICS / FABA than for REG-ICS OD-SABA unpublished results . This suggests that NON-REG OD-ICS / FABA may be an alternative therapy to REG-ICS OD-SABA in patients with mild to moderate asthma, and especially in those with poor adherence to conventional regular treatment. However, the ef cacy of NON-REG OD-ICS / FABA compared to the guideline-recommended conventional treatment is uncertain, and the ideal population of patients who may bene t from the treatment remains undefined. To examine these questions, we conducted a network meta-analysis of RCTs to assess the non-inferiority of NON-REG OD-ICS / FABA to REG-ICS OD-SABA in patients with mild asthma.
Methods

Publication search and inclusion criteria
MEDLINE source, PubMed , Scopus, and the Cochrane library database up to August 2016 were searched using the terms on-demand , as-needed , symptom-driven , and mild asthma . PubMed was mainly used for the publication search because it is an open access database that can be used for a comprehensive literature search. Scopus was used to ensure that all eligible articles were detected in PubMed. We also used the Cochrane library database to search for additional references. Embase was not used because it is unavailable in our institute. This is unlikely to have had a signi cant impact on the search results owing to the similarities between PubMed and Embase. No restrictions were imposed on the search language. A study was considered potentially eligible if it met the following criteria : 1 a RCT that assessed the clinical ef cacy of NON-REG OD-ICS / FABA, REG-ICS OD-SABA, or NON-REG OD-SABA in mild asthma ; and 2 it included asthma control as an outcome measure.
Data extraction and quality assessment
Studies in children aged 18 years or younger, non-English-language studies, case reports, and single arm studies were excluded. The methodological quality of the included trials was evaluated using the Jadad score, which assesses studies based on their description of randomization, blinding and dropout 7 .
Data analysis
A network meta-analysis was performed to compare the ef cacy of NON-REG OD-ICS / FABA with that of REG-ICS OD-SABA and NON-REG OD-SABA for asthma control, using the statistical method described by White 8 . The summary effect size is expressed as the mean difference MD . One advantage of a network meta-analysis is that the analysis can be performed even if the assessment of asthma control differs among the included RCTs because the methodological framework is based on the concept of a multivariable meta-analysis 8, 9 .
Non-inferiority for the incidence of asthma control was de ned as the upper 95 con dential intervals CIs for the MD estimated in the network meta-analysis being no higher than 0.1. Data analysis was performed using STATA ver. 14.0 Stata Corp., College Station, TX .
Ranking investigation
The probability of being the best treatment and the ranks of each treatment can be evaluated using statistical methods in a network meta-analysis. Thus, the calculated probability of being the best treatment, second best treatment, third best treatment, etc., can be determined. The surface under the cumulative ranking SUCRA curve, which is the ratio of the area under the cumulative ranking curve to the entire area in the plot, compares each treatment to an ideal best treatment, with a larger SUCRA value indicating a more effective treatment 8, 9 .
Inconsistency test
A network meta-analysis is carried out based on the assumption of consistency, which should be con rmed in a closed loop of evidence. The difference between direct and indirect evidence is expressed as the inconsistency factor, with 95
CIs and a P-value, and is calculated by analyzing the equality of direct and indirect evidence. CIs are truncated to zero because inconsistency factors represent the absolute difference between direct and indirect evidence. Loops in which the lower CI limit does not reach the zero line indicate that signi cant inconsistency is present 8, 9 .
Comparison-adjusted funnel plot
A comparison-adjusted funnel plot is a scatter plot that reveals the association between studyspecific effect sizes from the corresponding comparison-specific summary versus the inverted standard error. An asymmetrical funnel plot implies the presence of small-study effects, which re ect differences in effectiveness between small and large studies 8, 9 .
Results
Search results and characteristics of included studies
The study selection process is shown in Figure 1 . Nine citations were retrieved from the databases, of which 7 did not examine NON-REG OD-ICS / FABA. One article was identi ed from the reference lists of included studies. Finally, three RCTs were included in the network meta-analysis 4, 5, 10 . The characteristics of these studies are shown in Table 1 . NON-REG OD-ICS / FABA was included in 2 trials, REG-ICS OD-SABA in 3 trials, and NON-REG OD-SABA in 3 trials. All comparisons within the analysis are shown in Figure 2 . The mean age ranged from 28 to 45 years and the study duration ranged from 6 weeks to 6 months. The methods of evaluation of asthma differed among the three RCTs : the daytime asthma score was used in 2 RCTs, and the asthma control questionnaire score was used in one. The Jadad scores for the three studies ranged from 3 to 5, indicating that the included studies were of high quality.
Treatment comparison for asthma control in mild asthma
The results of a comparison of the ef cacy of the treatments for mild asthma control are shown in Table 2 
Analysis of ranking probability
The ranks of NON-REG OD-ICS / FABA, REG-ICS OD-SABA, and NON-REG OD-SABA are shown in Table 3 . The respective probabilities of being the best treatment were 91.2 , 8.8 , and 0.2 ; those for being the second best treatment were 8.6 , 79.0 , and 12.3 ; and those for being the third best treatment were 0.2 , 12.2 , and 87.6 Table 3 . The SUCRA values for NON-REG OD-ICS / FABA, REG-ICS OD-SABA, and NON-REG Results are expressed as mean differences MDs with 95 con dence intervals CIs . NON-REG OD-ICS / FABA : on-demand inhaled corticosteroid and fast-acting beta-2 agonist combination without any regular treatment ; REG-ICS OD-SABA : regular inhaled corticosteroid plus on-demand shortacting beta-2 agonist ; NON-REG OD-SABA : on-demand short-acting beta-2 agonist without any regular treatment ; NS : not signi cant. P 0.05 for differences between groups.
OD-SABA for asthma control were 1.0, 0.5, and 0.1, respectively Fig. 3 , Table 3 .
Inconsistency test
A funnel plot Fig. 4 showed symmetry to the line, which suggests that the network metaanalysis did not include a small-study effect. An inconsistency plot for direct and indirect Probabilities of being the best, second best, or third best treatment, calculated from the network meta-analysis, and SUCRA values for mild asthma control. NON-REG OD-ICS / FABA : on-demand inhaled corticosteroid and fast-acting beta-2 agonist combination without any regular treatment ; REG-ICS OD-SABA : regular inhaled corticosteroid plus on-demand short-acting beta-2 agonist ; NON-REG OD-SABA : on-demand short-acting beta-2 agonist without any regular treatment.
comparisons Fig. 5 suggested no signi cant inconsistency because the corresponding CI included zero.
Discussion
In this network meta-analysis, we showed non-inferiority of NON-REG OD-ICS / FABA for asthma control relative to REG-ICS OD-SABA, and superiority of NON-REG OD-ICS / FABA over NON-REG OD-SABA in patients with mild asthma. NON-REG OD-ICS / FABA also had the highest probability of being the best treatment and had the highest SUCRA value among the three treatments.
Previous RCTs have shown mixed results for asthma control after treatment with NON-REG OD-ICS / FABA, partially because of differences in the distribution of asthma severity and de nitions of complications [4] [5] [6] . In this study, we focused on mild asthma, and demonstrated non-inferiority of NON-REG OD-ICS / FABA to REG-ICS OD-SABA. As expected, the ef cacy of NON-REG OD-ICS / FABA for asthma control was superior to REG-ICS OD-SABA. This is plausible because an ICS and beta stimulant combination inhibits bronchoconstriction and suppresses airway in ammation. This is the rst network meta-analysis of the ef cacy of NON-REG OD-ICS / FABA focusing on mild asthma and this treatment was the highest ranked among the three treatments. We previously assessed non-inferiority of NON-REG OD-ICS / FABA to conventional best practice for asthma control or incidence of asthma exacerbation or aggravation in mild to moderate asthma not published . The results did not show non-inferiority of NON-REG OD-ICS / FABA to REG-ICS OD-SABA and REG-ICS / LABA OD-SABA. Taken together, those results and the current results suggest that NON-REG OD-ICS / FABA is effective as an alternative to the guideline-recommended conventional treatment in patients with mild asthma, rather than mild to moderate asthma, and especially in patients whose adherence to regular treatment is low. Several limitations of this study should be acknowledged. First, only three articles were 
